• 855-853-4760
  • customerservice@arevapharma.com

Media Center

Areva Pharmaceuticals is excited to announce another addition to our growing product portfolio – Temozolomide (oral capsule).

Temozolomide is an alkylating agent indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM), a type of primary brain cancer, for which it is given concomitantly with radiotherapy and then as maintenance treatment. Temozolomide is also indicated for the treatment of refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine; anaplastic astrocytoma is a type of cancer that can occur within the brain and spinal cord. Temozolomide capsules should not be opened or chewed. They should be swallowed whole with a glass of water. Storage: Room temperature; do not refrigerate. Please see our product page for more information. For orders, please contact your wholesaler or order direct via email: customerservice@arevapharma.com


Media Contact

Please direct all media inquiries to:

Customer Service at

customerservice@arevapharma.com

Areva Gallery